ORGANISATION/COMPANYUniversity of East Anglia
RESEARCH FIELDMedical sciences
RESEARCHER PROFILEFirst Stage Researcher (R1)
APPLICATION DEADLINE15/04/2018 23:00 - Europe/London
LOCATIONUnited Kingdom › Norwich
TYPE OF CONTRACTOther
There are more than 230,000 people living with blood cancer in the UK and 38,000 people are diagnosed with blood cancer each year. The three main groups are leukaemia, lymphoma and myeloma, but there are more than 130 individual types. Blood cancer is a malignant disorder characterized by accumulation of abnormal blood cells in bone marrow. Blood cancer is primarily a disease of the elderly. In younger patients (<65 years old), there is clear evidence of improved survival in the last two or three decades, however in the majority group of older patients, there is little evidence of similar improvement, and the appropriateness of intensive chemotherapy treatment represents a current dilemma. Accordingly, to improve outcomes for all patients (including older patients with blood cancer) there is a requirement for more effective treatments with reduced side effects.
This advertised project will advance our understanding of how the bone marrow environment promotes the survival and proliferation of abnormal blood cancer cells. Energy in the form of ATP is essential for the survival of all cells as it powers vital pathways and mitochondria are the major ATP producer in the cell.Cancer cells divide rapidly and mitochondria of tumour cells can become dysfunctional. We propose that the environment in which tumours live provide a recycling centre for exhausted dysfunctional mitochondria. To do this work we will employ in vitro assays with primary human blood cancer cells from the clinic at the Norfolk and Norwich University Hospital to determine how the environment helps to recycle mitochondria. We will then use in-vivo assays to confirm our in-vitro data.Together the data generated from this project will hopefully identify new therapeutic targets for these incurable diseases.
This PhD studentship is jointly funded for three years by Faculty of Medicine and Health Sciences and Rosetrees Trust. Funding comprises home/EU fees, an annual stipend of £14,777 and £1000 per annum to support research training. Overseas applicants may apply but are required to fund the difference between home/EU and overseas tuition fees (in 2018/19 the difference is £14,090 for the Norwich Medical School but are subject to an annual increase).
EURAXESS offer ID: 286406